close-icon

Log In to Bolder Science

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number

By completing and submitting this form, you agree to allow Bolder Science to collect the information provided and to receive communications from Bolder Science in the future regarding disease education and research updates.

close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Filter 10,687 trials Clear all
Filter by:

Sub-Study of the PREVIEW Study Australia

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Pre-diabetes, Obesity
    Pre-diabetes, Obesity
  • Phase Not Applicable
    Not Applicable
INTERVENTION

Behavioral: Low calorie diet administered from 0 to 2 months, Behavioral: High Protein / Low Glycaemic Index, Behavioral: Moderate Protein / High Glycaemic Index

Eligibility
  • Ages: 25 to 70 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Behavioral: Low calorie diet administered from 0 to 2 months, Behavioral: High Protein / Low Glycaemic Index, Behavioral: Moderate Protein / High Glycaemic Index

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

The University of Sydney, Camperdown, New South Wales, Australia

Brief Summary

The aim of this study is to investigate possible enduring effects of a standard 2-month weight loss program on appetite regulation, bone homeostasis and muscle strength in younger and older adults, as well as the impact of differences in dietary composition during weight maintenance.

Minimal Invasive Rehabilitation of Tooth Loss in the Posterior Segment (MIZE-S)

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Unsatisfactory or Defective Restoration of Tooth
    Unsatisfactory or Defective Restoration of Tooth
  • Phase Not Applicable
    Not Applicable
INTERVENTION

Device: all-ceramic inlay-retained RBFDP, Device: all-ceramic RBFDP

Eligibility
  • Ages: 18 to 89 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Device: all-ceramic inlay-retained RBFDP, Device: all-ceramic RBFDP

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Department of Prosthodontics, University Hospital Heidelberg, University of Heidelberg, Heidelberg, Baden-Württemberg, Germany

Brief Summary

Tooth loss can be addressed by different rehabilitative strategies. Implant-supported crowns and conventional bridges (fixed dental prostheses [FDPs]) are well established treatment alternatives. Implant therapy is sometimes impossible, however, because of patient-related risk factors or economic issues. In such cases therapy with an FDP requires extensive removal of tooth structure to provide enough space for the restoration and to ensure mechanical retention if the abutment teeth are sound. Alternatives for rehabilitation requiring minor or no preparation of the anchoring teeth are desirable. Resin-bonded bridges meet this demand for minimal invasiveness and have been used clinically successfully. Sometimes, however, patients choose a conventional FDP over a resin-bonded one (RBFDP) for esthetic reasons since the adhesive wings, which are traditionally made of a cobalt-chromium alloy, might be exposed while speaking or smiling or account for a colour change of the abutment teeth. Such patients profit from an all-ceramic RBFDP. Today, the clinical performance of different all-ceramic RBFDP designs has not yet been evaluated under randomized controlled conditions. The aim of this pilot study is to calculate the sample size that allows us to accept the hypothesis that the two designs tested are similar regarding their clinical performance with adequate statistical power.

Probing Cortical Excitability and Cognitive Function With TMS

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Cognitive Dysfunction
    Cognitive Dysfunction
  • Phase Not Applicable
    Not Applicable
INTERVENTION

Device: Transcranial Magnetic Stimulation (TMS)

Eligibility
  • Ages: 60 to 75 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Device: Transcranial Magnetic Stimulation (TMS)

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Arizona, Tucson, Arizona, United States

Brief Summary

The overarching purpose of this study is to develop a technique that is capable of identifying neurophysiological biomarkers sensitive enough to detect preclinical dementia by integrating Transcranial Magnetic Stimulation (TMS) and Functional Magnetic Resonance Imaging (fMRI). More specifically, this project has two specific aims: 1. To characterize cortical excitability and its relation to cognitive function using single-pulse TMS paradigm in Mild Cognitive Impairment (MCI) and healthy older adults. 2. To delineate cortical plasticity and its association to cognitive function using repetitive TMS paradigm and resting-state fMRI in MCI and healthy older adults. Techniques to artificially and precisely stimulate brain tissue are increasingly recognized as valuable tools both in clinical practice and in cognitive neuroscience studies among healthy individuals. Transcranial magnetic stimulation (TMS) is a non-invasive approach to stimulate the brain. Importantly, unlike other invasive brain stimulation techniques (e.g., surgical deep brain stimulation), no surgery, anesthesia, or sedation is involved. Instead, TMS involves placing a magnetic coil on the surface of the head. This coil then generates a magnetic field that is about the same strength as the magnetic field used by MRI machines, and when this magnetic field rapidly alternates, the neurons under the coil are excited. Extensive guidelines have been published by experts in the field to ensure safe use, and the thousands of patients & research participants who have received TMS in compliance with these guidelines demonstrate the safety of this practice. Depending on the method of use, TMS is very versatile -- it can be used to study research questions pertaining to the neural circuitry of the brain, it can be used as a diagnostic device, and it can be used therapeutically to treat various neurological conditions. In this study, the investigators intend to further study the potential for diagnostic applications of TMS. More specifically, TMS and brain imaging techniques will be used in combination in order to more sensitively diagnose dementia - perhaps even before symptoms emerge. Right now, there is no reliable method for doing so and it is difficult to distinguish between the forgetfulness of healthy aging and the early signs of disease. Our approach may provide a more sensitive diagnostic tool, which is likely to improve clinical outcomes.

Treatment of Cerebral Arteriovenous Malformations With SQUID Liquid Embolic Agent (CHOICE)

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Cerebral Arteriovenous Malformation
    Cerebral Arteriovenous Malformation
  • Phase N/A
    N/A
INTERVENTION

Device: SQUID non-adhesive liquid embolic agent

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Device: SQUID non-adhesive liquid embolic agent

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University Hospital Antwerp, Edegem, Belgium

Brief Summary

The objective of this study is to further establish that SQUID, an alternative liquid embolic agent with specific properties, is a safe and effective alternative in bAVM endovascular treatment strategy available to date. Therefore, the performance of SQUID will be documented and its safety of use will be confirmed in current practice.

Increasing Detection of Sub-Clinical Atrial Fibrillation in Defibrillator Patients With the Use of a VDD-ICD Lead

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Cardiac Arrhythmias, Atrial Fibrillation and Flutter, Cardiovascu...
    Cardiac Arrhythmias, Atrial Fibrillation and Flutter, Cardiovascu...
  • Phase Not Applicable
    Not Applicable
INTERVENTION

Device: VDD ICD (experimental group), Device: Single chamber VVI ICD (control group)

Eligibility
  • Ages: 51 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Device: VDD ICD (experimental group), Device: Single chamber VVI ICD (control group)

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Royal Alexandra Hospital, Edmonton, Alberta, Canada

Brief Summary

This study aims to compare the Dx-ICD system (experimental) to standard VVI-ICD (control) on the ability to diagnose silent AF in patients without prior AF receiving an ICD for standard indications.

Comparison of Cerebral SctO2 Between 36℃ and 33℃ of TTM After Cardiac Arrest

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Heart Arrest
    Heart Arrest
  • Phase Not Applicable
    Not Applicable
INTERVENTION

Device: Arctic Sun

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Device: Arctic Sun

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Seoul National University Hospital, Seoul, Korea, Republic of

Brief Summary

The investigators hypothesize that if decrease in SctO2 level is caused by the degree of hypothermia, SctO2 level in the 33-TH may be lower than that in the 36-TH group. if decrease in SctO2 level is not caused by the degree of hypothermia but caused by brain injury, SctO2 level may be associated with only the prognosis of cardiac arrest victims regardless of core temperatures. The primary objective of this study is to compare the 72-hour changes in SctO2 level between the 36-TH and 33-TH groups in cardiac arrest victims.

Remote Monitoring of CGM Data in Pediatric Patients With Newly Diagnosed Type 1 Diabetes (T1D)

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Type 1 Diabetes
    Type 1 Diabetes
  • Phase Not Applicable
    Not Applicable
INTERVENTION

Other: Integration with Epic

Eligibility
  • Ages: up to 21 / (18 to 64 years)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Other: Integration with Epic

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Lucile Packard Children's Hospital, Palo Alto, California, United States

Brief Summary

To determine if increased targeted contact between patients and the care team can improve diabetes outcomes in the 1st year after diagnosis. We will be using the GluVue platform to remotely view continuous glucose monitor (CGM) data. Based on alerts from GluVue, care team members will proactively reach out to patients and their families for more frequent dose adjustments. We will assess if remote monitoring facilitates contact between the care team and patients and improves glycemic control.

Molecular and Morphologic Characterization of Circulating Endothelial Cells

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Acute Myocardial Infarction
    Acute Myocardial Infarction
  • Phase N/A
    N/A
INTERVENTION

Not provided

Eligibility
  • Ages: 18 to 80 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Not provided

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Scrippshealth, La Jolla, California, United States

Brief Summary

The primary hypothesis of this study is that circulating endothelial cells (CECs) harbor key genetic and structural characteristics predisposing individuals to acute atherosclerotic plaque rupture and heart attack.

Cardiovascular Complications of Carfilzomib Treatment

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Not provided
    Not provided
  • Phase N/A
    N/A
INTERVENTION

Not provided

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
INTERVENTION

Not provided

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Brief Summary

Accumulating evidence supports the hypothesis of a pathophysiological role of the Ubiquitin Proteasome System (UPS) in the process of atherosclerosis and vascular function. However the data are contradicting in respect to the direction of this association and therefore the net effect of UPS activity on the cardiovascular system is not known. Inhibitors of UPS are currently standard of care for patients with multiple myeloma (MM). Heart failure and hypertension have been reported in studies of carfilzomib, an irreversible 2nd generation proteasome inhibitor, both as a single agent and in combination with other drugs but their potential vascular toxicity is not adequately studied. Furthermore, as the role of the UPS has not been studied yet clinically but only in experimental and autopsy based studies, assessment of UPS inhibition in humans would facilitate understanding of the UPS-mediated pathophysiologic mechanisms in human atherosclerosis. Thus, this project may stimulate further research on the role of UPS in atherogenesis and potential new therapeutic approaches on vascular dysfunction may arise. We designed the following project in order to investigate the acute and chronic effect of Carfilzomib (CFZ) on cardiovascular function. Patients with an indication to receive CFZ will be recruited to be followed in the Clinical Therapeutics Department in pre-specified timepoints. Functional and structural measurements including markers of arterial stiffness and subclinical atherosclerosis will be performed using non-invasive well-validated techniques. Blood pressure will be also evaluated using 24h hour ambulatory monitoring. Evaluation of cardiac function will be performed at baseline and thereafter at 6 months or earlier if a suspicious event occurs necessitating evaluation of cardiac function. In parallel and at each time point, the activity of UPS and intracellular levels of ubiquitin conjugates will be measured in peripheral blood mononuclear cells (PBMCs) and red blood cells (RBCs) using enzymatic proteasome activity assays and western blot techniques, respectively.

A Smartphone App to Improve Physical Activity

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Sedentary Lifestyle
    Sedentary Lifestyle
  • Phase Not Applicable
    Not Applicable
INTERVENTION

Other: Physical Activity (PA) Tracker App, Other: On Your Feet, Other: Coach Me, Other: Proof Positive

Eligibility
  • Ages: 65 to 84 Years (Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Other: Physical Activity (PA) Tracker App, Other: On Your Feet, Other: Coach Me, Other: Proof Positive

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Front Porch Center for Innovation and Wellbeing, Glendale, California, United States

Brief Summary

The purpose of this study is to develop, test, and optimize a physical activity (PA)-tracking smartphone app and specialty features, which are designed to facilitate older adults' PA by targeting common barriers in this population. For example, one feature sends messages throughout the day about the good things about growing older to combat negative views about aging which has been linked to decreased PA. Participants will include older adult smartphone users who are between the ages of 65 and 84 and are not very physically active. In phase one of the study, three groups of five older adults will be formed to test the PA-tracking app and one of three specialty features for a two-week period, followed by a focus group to learn about the older adults' experiences. In phase two, approximately 100 participants will be randomly assigned to one of eight groups that include various combinations of specialty features with the PA tracker, for the purpose of pilot testing the app for a four-month period. Testing will occur at the beginning and the end of the four-month intervention period, and will measure PA levels, sedentary activity time, self-reported PA, and functional mobility.